A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer. This is an ASCO Meeting Abstract from the 2015 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback